Journavx is finally in the wild. Widely touted as an opioid replacement, it hit the market this year — the first new type of non-opioid pain medication to be approved by the FDA in twenty years. [1] Most media coverage of Journavx has been extremely positive. The New Yorker: Scientists working in pain research described the underlying scientific achievement as “a magisterial first step,” “just marvellous,” and “the holy grail.” Okay, technically that was scientists being extreme...
